“This reminds us that with new uses of standard agents and introduction of new agents, it’s critical to carefully weigh the risks and benefits of systemic therapy,” Dr. Morton said.
The investigators plan to quantify risks associated with specific drugs and doses, she added.
The study was supported by the National Cancer Institute. Dr. Morton reported no relevant conflicts of interest to disclose.